Impact News +++ Corporate News: ABO Energy GmbH & Co. KGaA (EQS) +++ ABO ENERGY Aktie +3,03%

ACTINIUM Aktie

>ACTINIUM Aktienkurs

0.92 EUR -2.5% (TradegateBSX)

Ask: 0.963 EUR / 3127 Stück

Bid: 0.917 EUR / 3288 Stück

Tagesumsatz: 197 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ACTINIUM Aktie über LYNX handeln

Intraday

1 Jahr

>ACTINIUM Performance

1 Woche: -3,0%

1 Monat: -17,1%

3 Monate: -11,9%

6 Monate: -28,1%

1 Jahr: -8,5%

laufendes Jahr: -19,6%

>ACTINIUM Aktie

Name:

ACTINIUM PHARMAC. DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00507W2061 / A2QA48

Symbol/ Ticker:

7AY1 (Frankfurt)

Kürzel:

FRA:7AY1, ETR:7AY1, 7AY1:GR

Index:

Webseite:

https://www.actiniumpharm..

Profil:

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer. The company's primary aim is to harness the power of radiois..
>Volltext..

Marktkapitalisierung:

29.18 Mio. EUR

Unternehmenswert:

-15.35 Mio. EUR

Umsatz:

0.08 Mio. EUR

EBITDA:

-30.77 Mio. EUR

Nettogewinn:

-29.15 Mio. EUR

Gewinn je Aktie:

-0.93 EUR

Schulden:

0.96 Mio. EUR

Liquide Mittel:

44.98 Mio. EUR

Operativer Cashflow:

-21.1 Mio. EUR

Bargeldquote:

7.81

Umsatzwachstum:

5.43%

Gewinnwachstum:

19.76%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ACTINIUM

Letzte Datenerhebung:

16.02.26

>ACTINIUM Kennzahlen

Aktien/ Unternehmen:

Aktien: 31.2 Mio. St.

Frei handelbar: 96.88%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 37

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 403.62%

Bewertung:

KGV: -

KGV lG: -

KUV: 432.42

KBV: 2.61

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -810%

Gewinnmarge: -38443.33%

Operative Marge: -41486.67%

Managementeffizenz:

Gesamtkaprendite: -50.05%

Eigenkaprendite: -133.09%

>ACTINIUM Peer Group

Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung

>ACTINIUM Chart & Kurs - Tradegate

>ACTINIUM News

16.02.26 - 11:24	Eckert & Ziegler steigert Actinium-225-Produktion (4investors)
	Um den gesamten Artikel unter 4investors.de zu lesen, klicken Sie bitte auf die Überschrift...

16.02.26 - 11:03	Corporate News: Eckert & Ziegler SE (EQS)
	Eckert & Ziegler und UJF steigern Produktionsvolumen für Actinium-225 deutlich...

11.02.26 - 12:03	Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies (PR Newswire)
	Niowave has entered into a new agreement with Novartis to supply Actinium-225, a highly promising medical isotope The long-term supply agreement supports the development of next-generation therapies designed to precisely target and eliminate cancer cells LANSING, Mich., Feb. 11, 2026......

18.12.25 - 20:01	Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies (PR Newswire)
	Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement will help advance new radioconjugate therapies capable of precisely targeting and destroying cancer cells LANSING, Mich., Dec. 18, 2025 /PRNewswire/ --......

16.12.25 - 14:09	Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies (GlobeNewswire EN)
	Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors...

12.12.25 - 16:42	Actinium Pharmaceuticals: Aktie steigt nach vielversprechenden Daten zu Brustkrebstherapie/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.12.25 - 14:48	Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast (PR Newswire)
	- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 therapy trastuzumab - The Actinium-225 alpha-emitter payload of ATNM-400 induced......

03.12.25 - 11:45	Eckert & Ziegler liefert Actinium-225 an SK Biopharmaceuticals (4investors)
	Um den gesamten Artikel unter 4investors.de zu lesen, klicken Sie bitte auf die Überschrift...

03.12.25 - 10:48	Eckert & Ziegler To Supply SK Biopharmaceuticals With Actinium-225 To Boost Research, Development (AFX)
	SEOUL (dpa-AFX) - Eckert & Ziegler AG (EUZ.F, EUZ.DE), a German isotope technology components firm, said on Wednesday that it has agreed to supply Actinium-225, or Ac-225, to SK Biopharmaceuticals......

03.12.25 - 09:03	Corporate News: Eckert & Ziegler SE (EQS)
	Eckert & Ziegler und SK Biopharmaceuticals unterzeichnen Liefervertrag für Actinium-225...

01.12.25 - 14:48	Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium (PR Newswire)
	Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options ATNM-400 overcomes HER2 therapy resistance and represents a novel targeted radiotherapy with the potential to avoid off-target toxicities including......

17.11.25 - 14:42	Econ Corp Services DBA Investorideas.com: The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals′ (ATNM) Big Bet (Newsfile)
	Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking a......

04.11.25 - 13:33	Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications (PR Newswire)
	- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab - ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cancer (NSCLC),......

03.11.25 - 14:36	Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference (PR Newswire)
	NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be participating in the Stephens......

27.10.25 - 12:03	Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on (PR Newswire)
	- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT®) - Combination of......

24.10.25 - 14:33	Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
	- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology with continued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling potent activity independent of PSMA expression - ATNM-400 demonstrated superior efficacy......

13.10.25 - 18:12	Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
	ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally New preclinical findings demonstrate ATNM-400 overcomes resistance to the EGFR inhibitor osimertinib in......

13.10.25 - 14:33	Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
	- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression levels - Extended follow-up in prostate cancer models demonstrated durable anti-tumor......

11.09.25 - 14:09	Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 (GlobeNewswire EN)
	Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors...

03.09.25 - 14:09

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire EN)

FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company's novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Auf Kontinuität setzen vor allem die, denen noch nie etwas Neues eingefallen ist. - Dr. Fritz P. Rinnhofer

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram